ProteoNic Announces Licensing of Technology for Production of Biologics to Immunomedics, October 20, 2020

LEIDEN, Netherlands, Oct. 20, 2020 /PRNewswire/ — ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases. Under the agreement,…